Incidence of HANA Conditions in HIV-infected Individuals

  • STATUS
    Recruiting
  • days left to enroll
    54
  • participants needed
    150
  • sponsor
    Chinese University of Hong Kong
Updated on 24 January 2021
diabetes
insulin
hypertension
metabolic syndrome
HIV Infection
antiretroviral therapy
hiv antibody
insulin resistance
vitamin d
renal impairment
osteoporosis
AIDS
malnutrition
HIV Vaccine
fibrosis
vitamin d deficiency
vitamin
vitamins
dyslipidemia
osteopenia
lipodystrophy
hiv antibodies

Summary

With the availability of effective anti-retroviral therapy, HIV-infected individuals are expected not to die of AIDS and have longer life expectancy. But at the same time, HIV-associated non-AIDS (HANA) conditions are becoming more important in their clinical management. It is currently uncertain whether patients started on different anti-retroviral regimens will have different incidence of HANA conditions.

This study aims to evaluate the incidence of various HANA conditions in a cohort of newly diagnosed HIV-infected individuals in Hong Kong initiating anti-retroviral treatment. The incidence of various HANA conditions will be evaluated for those receiving INSTI versus other non-INSTI-based regimens.

The HANA conditions evaluated will include 1. Hypertension 2. Diabetes and insulin resistance 3. Dyslipidemia 4. Lipodystrophy 5. Metabolic syndrome 6. Osteopenia and osteoporosis 7. Vitamin D deficiency 8. Renal impairment and kidney tubular dysfunction and 9. Liver fibrosis. Patients will be assessed prior to initiation of anti-retroviral therapy, and 48 weeks and 96 weeks after initiation of treatment. The incidence of development of each HANA condition will be determined and compared between those initiated different anti-retroviral regimens.

Details
Condition Metabolic disorder, Osteopenia, HIV, HIV positive, Vitamin D Deficiency, HIV infection, Cirrhosis, Osteoporosis, AIDS Vaccines, Bone Diseases, Vitamin Deficiency, Metabolic syndrome, Renal Impairment, Renal Dysfunction, Impaired Renal Function, HIV (Pediatric), Hepatic Fibrosis, HIV Infections, Metabolic Disorders, kidney insufficiency, bone loss, low bone density, decreased bone mineral density, metabolic syndrome x, liver fibrosis, human immunodeficiency virus, hiv disease, HIV Vaccine, hiv vaccines
Clinical Study IdentifierNCT03483584
SponsorChinese University of Hong Kong
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Confirmed HIV infection by HIV antibody or RNA test
Age 40 years old
Anti-retroviral treatment nave
Agree to initiate anti-retroviral therapy (ART) as determined by in-charge HIV physician

Exclusion Criteria

Pregnancy
Unable to give informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note